CASE REPORT ON ANTI-TUBERCULOSIS INDUCED CIRRHOSIS
Abstract
Tuberculosis is well known disease for centuries and is the major problem widely seen all over the world. It is the significant cause for morbidity and mortality. The standard treatment for tuberculosis is isoniazid, rifampicin, pyranzinamide, ethambutol, streptomycin. Regarding the standard treatment there is one of the most common cause is liver failure, which is drug induced. Among the anti-tuberculosis drug isoniazid , rifampicin and pyrazinamide cause hepatotoxicity is the leading cause in India. Most of the patient have to be counseled regarding the treatment adherence and its adverse effect of the drug.
Keywords:
Tuberculosis, isoniazid, hepatotoxicity
Downloads
Download data is not yet available.
References
1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–21.
2. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5:231–49.
3. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192–202.
4. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–52.
5. Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol. 2010;7:543–56.
6. Kumar R, Shalimar, Bhatia V, Khanal S, Sreenivas V, Gupta SD, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665–74.
7. Devarbhavi H, Dierkhising R, Kremers WK. Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatology. 2010;52:798–9.
8. . Benichou C. Criteria for drug-induced liver disorder: report of an international consensus meeting. J Hepatol 1990;11:272–276.
9. Schenker S,Martin RR,Hoyumpa AM.Antecedent liver disease and drug toxicity.J Hepatol 1999;31: 1098-1105 [PMID:10604586 DOI:10.1016/S0168-8278(99)80325-0].
10. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville, MD: Division of AIDS, National Insttute of Allergy and Infectious Diseases; 1996.
11. Saigal S, Agarwal SR, Nandeesh HP, Sarin S. Safety of an ofloxacin-based antitubercular regimen for the treatment of the tuberculosis in patients with underlying chronic liver disease;a prelimeinary report .J Gastroenterol Hepatol 2001;16: 1028-1032 {PMID:119595068 DOI:10.1046/j.1440-1746.2001.02570.x]
12. Warrington RJ, McPhilips‐Feener S, Rutherford WJ. The predictive value of the lymphocyte transformation test in isoniazid‐associated hepatitis. Clin Allergy 1982; 12: 217–22.
13. Warrington RJ, Tse KS, Gorski BA, Schwenk R, Sehon AH. Evaluation of isoniazid‐associated hepatitis by immunological tests. Clin Exp Immunol 1978; 32: 97–104.
14. Metushi IG, Sanders C, Acute Liver Study G, Lee WM, Uetrecht J. Detection of anti‐isoniazid and anti‐cytochrome P450 antibodies in patients with isoniazid‐induced liver failure. Hepatology 2014; 59: 1084–93.
15. 15. Huang J.H., Zhang C., Zhang D.G., Li L., Chen X., Xu D.X. Rifampicin-induced hepatic lipid accumulation: Association with up-regulation of peroxisome proliferator-activated receptor gamma in mouse liver. PLoS ONE. 2016;11:e0165787. doi: 10.1371/journal.pone.0165787.
16. Chowdhury A., Santra A., Bhattacharjee K., Ghatak S., Saha D.R., Dhali G.K. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J. Hepatol. 2006;45:117–126. doi: 10.1016/j.jhep.2006.01.027
17. CDC: Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR 2003; 52 (31):735-9.
2. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5:231–49.
3. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192–202.
4. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–52.
5. Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol. 2010;7:543–56.
6. Kumar R, Shalimar, Bhatia V, Khanal S, Sreenivas V, Gupta SD, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665–74.
7. Devarbhavi H, Dierkhising R, Kremers WK. Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatology. 2010;52:798–9.
8. . Benichou C. Criteria for drug-induced liver disorder: report of an international consensus meeting. J Hepatol 1990;11:272–276.
9. Schenker S,Martin RR,Hoyumpa AM.Antecedent liver disease and drug toxicity.J Hepatol 1999;31: 1098-1105 [PMID:10604586 DOI:10.1016/S0168-8278(99)80325-0].
10. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville, MD: Division of AIDS, National Insttute of Allergy and Infectious Diseases; 1996.
11. Saigal S, Agarwal SR, Nandeesh HP, Sarin S. Safety of an ofloxacin-based antitubercular regimen for the treatment of the tuberculosis in patients with underlying chronic liver disease;a prelimeinary report .J Gastroenterol Hepatol 2001;16: 1028-1032 {PMID:119595068 DOI:10.1046/j.1440-1746.2001.02570.x]
12. Warrington RJ, McPhilips‐Feener S, Rutherford WJ. The predictive value of the lymphocyte transformation test in isoniazid‐associated hepatitis. Clin Allergy 1982; 12: 217–22.
13. Warrington RJ, Tse KS, Gorski BA, Schwenk R, Sehon AH. Evaluation of isoniazid‐associated hepatitis by immunological tests. Clin Exp Immunol 1978; 32: 97–104.
14. Metushi IG, Sanders C, Acute Liver Study G, Lee WM, Uetrecht J. Detection of anti‐isoniazid and anti‐cytochrome P450 antibodies in patients with isoniazid‐induced liver failure. Hepatology 2014; 59: 1084–93.
15. 15. Huang J.H., Zhang C., Zhang D.G., Li L., Chen X., Xu D.X. Rifampicin-induced hepatic lipid accumulation: Association with up-regulation of peroxisome proliferator-activated receptor gamma in mouse liver. PLoS ONE. 2016;11:e0165787. doi: 10.1371/journal.pone.0165787.
16. Chowdhury A., Santra A., Bhattacharjee K., Ghatak S., Saha D.R., Dhali G.K. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J. Hepatol. 2006;45:117–126. doi: 10.1016/j.jhep.2006.01.027
17. CDC: Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR 2003; 52 (31):735-9.
Published
10/12/2020
Statistics
173 Views | 147 Downloads
Citatons
How to Cite
Jyotsna Allamsetty, Syam Prasanth Peddada, Padma Priya D, and Premakumari Nimmala. “CASE REPORT ON ANTI-TUBERCULOSIS INDUCED CIRRHOSIS”. International Journal of Alternative and Complementary Medicine, Dec. 2020, pp. 49-54, https://saapjournals.org/index.php/ijacm/article/view/129.
Issue
Section
Case Study
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
.